← Leaderboards
Shu-Wing Ng
Brigham And Women'S Hospital
$2,382,851
Attributed
$2,382,851
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $230.7K · FY2005–11$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$2,382,851 · 5
By mechanism
R21$1,101,317 · 3
R01$1,044,234 · 1
R29$237,300 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Frederick Bradley Johnson$7,689,908
- Eunjung Alice Lee$9,641,765
- Rong Tian$29,765,984
- Mitzi Kuroda$13,240,681
- Shiladitya Sengupta$10,066,982
Others in their field
Top investigators on “Gene Expression”
- Jeffrey P Krischer · University Of South Florida$137,481,663
- Eric S Lander · Whitehead Institute For Biomedical Res$128,154,716
- Stacey Gabriel · Massachusetts Institute Of Technology$86,302,566
- Bruce W Stillman · Cold Spring Harbor Laboratory$82,324,317
- Michael P Snyder · Yale University$75,701,723
- Ronald G Crystal · Weill Medical College Of Cornell Univ$74,774,977
Research focus
Gene ExpressionHuman TissueEnzyme ActivityFlow CytometryProtein Protein InteractionBiomarkerTranscription FactorHelicaseMolecular CloningCell SenescenceBiochemistryProtein Structure FunctionYeast Two Hybrid SystemProtein IsoformsDna TopoisomerasesCell Growth RegulationGenetic RecombinationComplementary DnaClinical ResearchOvary NeoplasmsCancer PatientCancer Cell LineBinding ProteinsCancer Cell
Grant awards (12)
Targeting lipid metabolic and signaling enzyme in ovarian cancer$230,673
R21 · FY2011 · CA · contact PI
Targeting lipid metabolic and signaling enzyme in ovarian cancer$217,918
R21 · FY2010 · CA · contact PI
XIST RNA and Ovarian Cancer$155,700
R21 · FY2005 · CA
XIST RNA and Ovarian Cancer$155,700
R21 · FY2004 · CA
TOPOISOMERASE III AND GENOMIC INSTABILITY$254,250
R01 · FY2003 · GM
Biomarkers for Ovarian Cancer$173,000
R21 · FY2003 · CA
TOPOISOMERASE III AND GENOMIC INSTABILITY$254,250
R01 · FY2002 · GM
Biomarkers for Ovarian Cancer$168,326
R21 · FY2002 · CA
TOPOISOMERASE III AND GENOMIC INSTABILITY$254,250
R01 · FY2001 · GM
TOPOISOMERASE II EXPRESSION IN DRUG RESISTANCE$118,650
R29 · FY2001 · CA
TOPOISOMERASE III AND GENOMIC INSTABILITY$281,484
R01 · FY2000 · GM
TOPOISOMERASE II EXPRESSION IN DRUG RESISTANCE$118,650
R29 · FY2000 · CA